mRNA-tLNP-Levostar Biotech_Innovative Solutions for Innovative Therapies

Services

Home

mRNA-tLNP

In vivo CAR-T is reshaping the future of cancer therapy by enabling T cells to be engineered directly inside the patient, eliminating the need for complex ex vivo cell manufacturing. To achieve this breakthrough, precision delivery is essential. Antibody-conjugated lipid nanoparticles (mRNA-tLNPs) provide a powerful solution, combining the efficiency of mRNA-LNP delivery with the targeting ability of antibodies. By directing genetic payloads specifically to T cells, this technology drives selective in vivo CAR expression, reduces off-target effects, and enhances therapeutic potential. mRNA-tLNPs thus play a pivotal role in making in vivo CAR-T not only possible, but scalable and clinically accessible.

At Levostar, we provide comprehensive tLNP services, from design and formulation to rigorous analytical testing. Leveraging our proprietary nano-flow platform, we deliver accurate characterization of critical quality attributes, including particle size distribution, antibody positivity rate, and copy number. This ensures reliable performance of Ab-LNP systems for both research and translational applications.

Service Advantages

· Custom mRNA Synthesis: Proprietary mRNA plasmid platform addressing multiple challenges, including poly(A) stability and supercoiled multimers.
· Flexible Antibody Conjugation Options: Compatible with diverse targeting antibodies such as CD8, CD3, CD5, and CD7.
· Multiple Antibody Formats: Full-length IgG, Fab, and scFv available for flexible targeting.
· Custom Antibody Synthesis Service: Antibodies can be synthesized based on provided sequences and subsequently conjugated to LNPs.

· Exclusive tLNP Nano-Flow Analysis: Comprehensive assessment including antibody conjugation efficiency, particle size distribution, antibody positivity rate, and copy number profiling.

Service Details

	QC Specifications
Scale：100 μg-10 mg	pH：6.0-8.0
Antibody Name：CD3,CD5,CD7,CD8,others	Size Distribution：40-180 nm
Antibody Type：Full Ab, scFv, Fab, VHH, etc	PDI：≤ 0.5
Turnaround Time：10-15 BD	RNA Content：0.1- 0.5 mg/ml
Shipping Condition：Dry ice, Single freeze/thaw cycle	*Encapsulation Efficiency：≥ 85%
Shipping Condition：Dry ice, Single freeze/thaw cycle	*Positivity Rate: ≥ 90%

* are optional testing require additional charge

Validation of CD8-Targeted LNP Binding Specificity

After anti-CD8 antibodies were conjugated to LNPs, the resulting tLNPs generated strong and stable targeted fluorescent signals in the CD8 target system, whereas the control group showed markedly reduced signal intensity. In PBMCs, the tLNPs specifically bound to CD8⁺ T cells, with imaging results consistent with flow cytometry data. These findings validate the targeting specificity and system stability of the antibody-conjugated LNP platform.

Antibody-conjugated mRNA-LNP characterization

Validation of CD8-Targeted LNP Binding Specificity

mRNA-tLNP characterization

Particle size – Determines the distribution and uniformity of LNPs, directly impacting stability, biodistribution, and delivery efficiency.

Antibody conjugation positivity rate – Evaluates the surface modification efficiency for targeted delivery applications.

CD3-LNP

CD5-LNP

CD8-LNP

Antibody conjugation copy number

The LNP antibody conjugation copy number refers to the average number of antibody molecules successfully conjugated to each lipid nanoparticle (LNP).

FAQ

What is targeted LNP (tLNP) and how does it work for mRNA delivery?

Targeted lipid nanoparticles (tLNPs) are advanced delivery systems designed to transport mRNA to specific cell types. Unlike conventional LNPs, tLNPs are functionalized with targeting ligands such as antibodies or peptides that recognize cell surface markers.This enables selective delivery of mRNA to target cells, improving delivery efficiency while reducing off-target distribution.

How can targeted LNP deliver mRNA to T cells or immune cells?

tLNPs can be engineered with ligands that bind to specific receptors on T cells or other immune cells. Once bound, the nanoparticles are internalized through receptor-mediated endocytosis, allowing the encapsulated mRNA to be released into the cytoplasm.This targeted approach enhances delivery precision and is particularly useful for applications such as in vivo CAR-T generation and immune cell engineering.

What are the advantages of targeted LNP over conventional LNP?

Compared to conventional LNPs, targeted LNPs offer improved cell specificity, reduced off-target effects, and enhanced therapeutic efficiency.While standard LNPs tend to accumulate in organs such as the liver, tLNPs can be directed to specific cell populations, enabling lower dosing requirements and more controlled biological responses. This makes them highly valuable for next-generation mRNA therapeutics.

How far can Levostar support the t-LNP projects?

Levostar can provide end-to-end solutions, including payloads synthesis, LNP foumulation choices, antibody conjugation, and final QC.

What is nano flow cytometry?

Nano flow cytometry is an unique QC method desinged by Levsotar. It collects fluorescence intensity to quantify the LNP antibody conjugation positive rate and antibody copy number per LNP. This rapid and precise quantification is essential for t-LNP proejcts.